Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study Meeting Abstract
| Authors: | Krug, U.; Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E.; Erba, H. P.; Pigneux, A.; Horst, H. A.; Recher, C.; Klimek, V. M.; Cortes, J.; Roboz, G. J.; Craig, A. R.; Fox, J. A.; Ward, R.; Smith, J. A.; Acton, G.; Mehta, C.; Kantarjian, H. M.; Stuart, R. K. |
| Abstract Title: | Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 38 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2015 Oct 9-13 |
| Meeting Location: | Basel, Switzerland |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2015-10-01 |
| Start Page: | 121 |
| Language: | English |
| ACCESSION: | WOS:000364268800287 |
| PROVIDER: | wos |
| PUBMED: | 26461956 |
| DOI: | 10.1159/000439070 |
| Notes: | Meeting Abstract: V424 -- [Annual Meeting of the German, Austrian and Swiss Societies for Haematology and Medical Oncology] -- Source: Wos |
